The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

July 22, 2022

Study Completion Date

December 31, 2025

Conditions
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

Ponatinib 30mg OD

Ponatinib 30mg OD

DRUG

Ponatinib 45mg OD

Ponatinib 45mg OD

Trial Locations (14)

Unknown

Anhui Provincial Hospital, Hefei

The First Affiliated Hospital of Anhui Medical University, Hefei

Nanfang Hospital of Southern Medical University, Guangzhou

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Xiangya Hospital Central South University, Changsha

The First Affiliated Hospital of Soochow University, Suzhou

Shengjing Hospital of China Medical University, Shenyang

Qilu Hospital of Shandong University, Jinan

Second hospital of Shanxi Medical University, Taiyuan

Shenzhen Second People's Hospital, Shenzhen

West China Hospital, Sichuan University, Chengdu

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

1st affiliated hospital, Peking University, Beijing

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY